Lisa A Jackson1, Hana M El Sahly2, Sarah George3, Patricia Winokur4, Kathryn Edwards5, Rebecca C Brady6, Nadine Rouphael7, Wendy A Keitel2, Mark J Mulligan7, Robert L Burton8, Aya Nakamura9, Jennifer Ferreria9, Moon H Nahm8. 1. Kaiser Permanente Washington Health Research Institute, Seattle, WA, United States. Electronic address: Jackson.L@ghc.org. 2. Departments of Molecular Virology & Microbiology and Medicine, Baylor College of Medicine, Houston, TX, United States. 3. Division of Infectious Diseases, Allergy, & Immunology, Saint Louis University School of Medicine, and St. Louis VA Medical Center, St. Louis, MO, United States. 4. University of Iowa and Iowa City VA Medical Center, Iowa City, IA, United States. 5. Vanderbilt Vaccine Research Program, Division of Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, United States. 6. Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States. 7. The Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Decatur, GA, United States. 8. Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States. 9. The Emmes Corporation, Rockville, MD, United States.
Abstract
INTRODUCTION: In older adults, prior administration of 23-valent pneumococcal polysaccharide vaccine (PPSV23) blunts the opsonophagocytic antibody (OPA) response to subsequent administration of 13-valent pneumococcal conjugate vaccine (PCV13). To determine whether a higher dose of PCV13 could mitigate this effect in adults 55 through 74 years of age, we compared OPA responses to a double dose of PCV13 in persons previously vaccinated with PPSV23 with responses to a single dose of PCV13 in previously vaccinated persons, and with a single dose in PPSV23 naïve persons. METHODS: Subjects previously vaccinated with PPSV23 were randomly assigned to receive either a single injection or two concurrent injections of 0.5 mL PCV13. Naïve subjects received a single injection of 0.5 mL PCV13. Serotype-specific OPA responses to 12 of the PCV13 serotypes were assessed on samples collected on Day 29 and Day 181. Comparisons of the OPA titers between study groups were based on the lower bound of the 95% confidence interval of the log geometric mean ratio to define superiority (>1) and non-inferiority (>0.5). RESULTS: At Day 29, the OPA responses to one dose in previously vaccinated (n = 284) versus one dose in naïve subjects (n = 311) achieved the threshold for non-inferiority for only 3 of the 12 serotypes. In previously vaccinated subjects, responses to a double dose (n = 288) versus a single dose met the threshold for superiority for 7 serotypes. The responses to a double dose in previously vaccinated subjects versus a single dose in naïve subjects met the threshold for non-inferiority for 9 serotypes. CONCLUSIONS: There is a dose response to PCV13 in older adults and the higher response to a double dose in previously vaccinated adults is non-inferior to that of a single dose in naïve adults for 9 of the 12 PCV13 serotypes evaluated.
INTRODUCTION: In older adults, prior administration of 23-valent pneumococcal polysaccharide vaccine (PPSV23) blunts the opsonophagocytic antibody (OPA) response to subsequent administration of 13-valent pneumococcal conjugate vaccine (PCV13). To determine whether a higher dose of PCV13 could mitigate this effect in adults 55 through 74 years of age, we compared OPA responses to a double dose of PCV13 in persons previously vaccinated with PPSV23 with responses to a single dose of PCV13 in previously vaccinated persons, and with a single dose in PPSV23 naïve persons. METHODS: Subjects previously vaccinated with PPSV23 were randomly assigned to receive either a single injection or two concurrent injections of 0.5 mL PCV13. Naïve subjects received a single injection of 0.5 mL PCV13. Serotype-specific OPA responses to 12 of the PCV13 serotypes were assessed on samples collected on Day 29 and Day 181. Comparisons of the OPA titers between study groups were based on the lower bound of the 95% confidence interval of the log geometric mean ratio to define superiority (>1) and non-inferiority (>0.5). RESULTS: At Day 29, the OPA responses to one dose in previously vaccinated (n = 284) versus one dose in naïve subjects (n = 311) achieved the threshold for non-inferiority for only 3 of the 12 serotypes. In previously vaccinated subjects, responses to a double dose (n = 288) versus a single dose met the threshold for superiority for 7 serotypes. The responses to a double dose in previously vaccinated subjects versus a single dose in naïve subjects met the threshold for non-inferiority for 9 serotypes. CONCLUSIONS: There is a dose response to PCV13 in older adults and the higher response to a double dose in previously vaccinated adults is non-inferior to that of a single dose in naïve adults for 9 of the 12 PCV13 serotypes evaluated.
Authors: Lisa A Jackson; Kathleen M Neuzil; Moon H Nahm; Cynthia G Whitney; Onchee Yu; Jennifer C Nelson; Pat T Starkovich; Maya Dunstan; Barbara Carste; David K Shay; James Baggs; George M Carlone Journal: Vaccine Date: 2007-03-12 Impact factor: 3.641
Authors: Richard N Greenberg; Alejandra Gurtman; Robert W Frenck; Cynthia Strout; Kathrin U Jansen; James Trammel; Daniel A Scott; Emilio A Emini; William C Gruber; Beate Schmoele-Thoma Journal: Vaccine Date: 2014-03-05 Impact factor: 3.641
Authors: Marc J M Bonten; Susanne M Huijts; Marieke Bolkenbaas; Chris Webber; Scott Patterson; Samantha Gault; Cornelis H van Werkhoven; Anna M M van Deursen; Elisabeth A M Sanders; Theo J M Verheij; Michael Patton; Anne McDonough; Anita Moradoghli-Haftvani; Helen Smith; Tracey Mellelieu; Michael W Pride; Graham Crowther; Beate Schmoele-Thoma; Daniel A Scott; Kathrin U Jansen; Rita Lobatto; Bas Oosterman; Nils Visser; Esther Caspers; Andre Smorenburg; Emilio A Emini; William C Gruber; Diederick E Grobbee Journal: N Engl J Med Date: 2015-03-19 Impact factor: 91.245
Authors: Rajeka Lazarus; Elizabeth Clutterbuck; Ly-Mee Yu; Jaclyn Bowman; Elizabeth A Bateman; Linda Diggle; Brian Angus; Tim E Peto; Peter C Beverley; David Mant; Andrew J Pollard Journal: Clin Infect Dis Date: 2011-03-15 Impact factor: 9.079
Authors: H Lode; B Schmoele-Thoma; W Gruber; N Ahlers; P Fernsten; S Baker; A Razmpour; G Siber; J Hackell; S Lockhart; O Burkhardt; T Welte; A de Roux Journal: Vaccine Date: 2011-05-17 Impact factor: 3.641
Authors: Matthew R Moore; Ruth Link-Gelles; William Schaffner; Ruth Lynfield; Catherine Lexau; Nancy M Bennett; Susan Petit; Shelley M Zansky; Lee H Harrison; Arthur Reingold; Lisa Miller; Karen Scherzinger; Ann Thomas; Monica M Farley; Elizabeth R Zell; Thomas H Taylor; Tracy Pondo; Loren Rodgers; Lesley McGee; Bernard Beall; James H Jorgensen; Cynthia G Whitney Journal: Lancet Infect Dis Date: 2015-02-03 Impact factor: 25.071
Authors: Stephen I Pelton; Kimberly M Shea; Derek Weycker; Raymond A Farkouh; David R Strutton; John Edelsberg Journal: Open Forum Infect Dis Date: 2015-03-20 Impact factor: 3.835
Authors: Sara Tomczyk; Nancy M Bennett; Charles Stoecker; Ryan Gierke; Matthew R Moore; Cynthia G Whitney; Stephen Hadler; Tamara Pilishvili Journal: MMWR Morb Mortal Wkly Rep Date: 2014-09-19 Impact factor: 17.586
Authors: Nadine G Rouphael; Cecilia Morgan; Shuying S Li; Ryan Jensen; Brittany Sanchez; Shelly Karuna; Edith Swann; Magdalena E Sobieszczyk; Ian Frank; Gregory J Wilson; Hong-Van Tieu; Janine Maenza; Aliza Norwood; James Kobie; Faruk Sinangil; Giuseppe Pantaleo; Song Ding; M Juliana McElrath; Stephen C De Rosa; David C Montefiori; Guido Ferrari; Georgia D Tomaras; Michael C Keefer Journal: J Clin Invest Date: 2019-11-01 Impact factor: 14.808